购物车
- 全部删除
- 您的购物车当前为空
ARD-266 is a highly potent VHL E3 ligase-based androgen receptor (AR) PROTAC degrader, effectively inducing AR protein degradation in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines (DC50s: 0.2-1 nM).
ARD-266 is a highly potent VHL E3 ligase-based androgen receptor (AR) PROTAC degrader, effectively inducing AR protein degradation in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines (DC50s: 0.2-1 nM).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100 mg | 询价 | 期货 | |
500 mg | 询价 | 期货 |
产品描述 | ARD-266 is a highly potent VHL E3 ligase-based androgen receptor (AR) PROTAC degrader, effectively inducing AR protein degradation in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines (DC50s: 0.2-1 nM). |
体外活性 | ARD-266 (Compound 11; 100 nM; 1-24 hours; LNCaP and VCaP cells) reduces AR protein levels within 3 hours, achieving near-complete AR elimination after 6 hours in LNCaP cells. ARD-266 (1-10000 nM; 24 hours; LNCaP cells) also suppresses PSA, TMPRSS2, and FKBP5 gene expression in a dose-dependent manner, reducing mRNA levels by over 50% at 10 nM in LNCaP cells. |
分子量 | 915.51 |
分子式 | C52H59ClN6O7 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容